AUM and trading activity drives Oppenheimer's wealth management business. Read why we remain bullish on OPY stock.

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

Alphabet (GOOGL) will be stepping up to the earnings plate tomorrow (February 4), when it will deliver its fourth quarter ...

Over the years, we’ve heard hundreds of time about how we have enough nuclear weapons to destroy the world. But is that ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

After the music industry gave out its prestigious Grammys Sunday, the film community is gearing up for its ceremony to take ...

After devastating wildfires tore through Los Angeles, the 97th Academy Awards are going forward. The academy on Wednesday ...

Patient Capital Management stated the following regarding Coinbase Global, Inc. (NASDAQ:COIN) in its Q4 2024 investor letter: ...

Last year’s Oscar winners Emma Stone, Cillian Murphy, Da’Vine Joy Randolph and Robert Downey Jr. are set to return to the ...

Albemarle (NYSE:ALB – Get Free Report) was downgraded by research analysts at Evercore ISI from an “outperform” rating to an ...

Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present ...